Publications by authors named "Ayad E Shafiq"

3 Publications

  • Page 1 of 1

Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case series.

Br J Ophthalmol 2018 02 27;102(2):260-264. Epub 2017 Jun 27.

Department of Ophthalmology, Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, UK.

Background: Intravitreal bevacizumab (IVB) has emerged as an effective treatment modality for the management of retinopathy of prematurity (ROP) where the disease is severe and posterior. Despite evidence of systemic vascular endothelial growth factor suppression and concerns about how this might affect the developing neonate, the optimal dose is unknown to date. We report our experience of using ultra-low-dose (0.16 mg) IVB, one-quarter of the 'standard' dose that has widely been reported in the treatment of ROP.

Methods: A retrospective observational case series of consecutive infants who underwent ultra-low-dose IVB injection for the management of ROP at a regional neonatal intensive care unit in the North East of England, between November 2013 and August 2016.

Results: 29 eyes of 15 infants underwent IVB injection. We defined 'treatment success' as complete regression of retinopathy and vascularisation into (or laser ablation of) zone 3. Primary success (in response to IVB 0.16 mg alone) was observed in 23/29 eyes (79.3%). Secondary success (where additional treatment was required) was observed in 27/29 eyes (93.1%). One infant died of respiratory disease during follow-up. Retreatment occurred in 6/29 eyes (20.6%). Retreatments occurred at a mean of 9.8 weeks after initial IVB (range 6-15) and at a mean of 44 weeks postmenstrual age (range 40-50).

Conclusion: 0.16 mg IVB is effective in the treatment of severe and posterior ROP, with no adverse ocular outcomes occurring in our series.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1136/bjophthalmol-2017-310408DOI Listing
February 2018

Corneal endothelial dysfunction in Pearson syndrome.

Ophthalmic Genet 2013 Mar-Jun;34(1-2):55-7. Epub 2011 Sep 21.

Department of Ophthalmology, Southport and Ormskirk Hospital NHS Trust, Southport, UK.

Mitochondrial disorders are associated with well recognized ocular manifestations. Pearson syndrome is an often fatal, multisystem, mitochondrial disorder that causes variable bone marrow, hepatic, renal and pancreatic exocrine dysfunction. Phenotypic progression of ocular disease in a 12-year-old male with Pearson syndrome is described. This case illustrates phenotypic drift from Pearson syndrome to Kearns-Sayre syndrome given the patient's longevity. Persistent corneal endothelial failure was noted in addition to ptosis, chronic external ophthalmoplegia and mid-peripheral pigmentary retinopathy. We propose that corneal edema resulting from corneal endothelial metabolic pump failure occurs within a spectrum of mitochondrial disorders.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3109/13816810.2011.610862DOI Listing
August 2013

Surgical outcome for removal of subfoveal choroidal neovascular membranes in children.

Retina 2002 Aug;22(4):412-7

Department of Ophthalmology, Toronto Western Hospital, Ontario, Canada.

Objective: To asses the surgical outcome of subfoveal choroidal neovascular membranes in children.

Methods: Two eyes with Best disease and one with idiopathic subfoveal choroidal neovascular membrane underwent vitrectomy and extraction of the subfoveal neovascular membrane.

Results: All the three eyes had significant improvement in their visual acuity and there was no recurrence of choroidal neovascular membrane.

Conclusion: Surgical removal of subfoveal choroidal neovascular membrane in children carries good visual prognosis in selected cases.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1097/00006982-200208000-00003DOI Listing
August 2002